| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1023239822 |
| P356 | DOI | 10.2165/00003088-198106050-00001 |
| P698 | PubMed publication ID | 7037261 |
| P2093 | author name string | G R Wilkinson | |
| R A Branch | |||
| R K Verbeeck | |||
| P2860 | cites work | The specificity of the digoxin radioimmunoassay procedure | Q69389764 |
| Inhibition of Phenylbutazone Elimination by Its Metabolite Oxyphenbutazone | Q69401560 | ||
| Elimination of isoniazid in patients with impaired renal function | Q69606769 | ||
| Quinidine Elimination in Patients with Congestive Heart Failure or Poor Renal Function | Q69737872 | ||
| Urinary Excretion and Plasma Levels of Sulphonamides in Patients with Renal Impairment | Q69918648 | ||
| The acetylator phenotype of patients with systemic lupus erythematosus | Q70043897 | ||
| Conjugation of methyldopa in renal failure | Q70381939 | ||
| Hypotensive effect of methyldopa in renal failure associated with hypertension | Q70390594 | ||
| The biotransformation of oxazepam (7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one) in man, miniature swine and rat | Q70469510 | ||
| Inhibition of diphenylhydantoin elimination by its major metabolite | Q70485268 | ||
| Disposition of 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one (lorazepam) in humans. Determination of the drug by electron capture gas chromatography | Q70574198 | ||
| Metabolic disposition of methyldopa in hypertensive and renal-insufficient children | Q71129089 | ||
| The question of cumulation of digoxin metabolites in renal failure | Q71132175 | ||
| Effect of hemodialysis on propoxyphene and norpropoxyphene concentrations in blood of anephric patients | Q71140992 | ||
| Binding to cytochrome P-450 and metabolism of desmethylimipramine and metabolites in rat liver microsomes | Q71148872 | ||
| The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites | Q71156663 | ||
| Pharmacokinetics of acebutolol in patients with all grades of renal failure | Q71329818 | ||
| Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment | Q71979309 | ||
| Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function | Q72421111 | ||
| The metabolism of tritiated digoxin in renal insufficiency in dogs and man | Q72808560 | ||
| Administration of tritiated digoxin with and without a loading dose. A metabolic study | Q72812512 | ||
| The effect of N-demethylation on certain pharmacologic actions of morphine, codeine, and meperidine in the mouse | Q73662947 | ||
| THE METABOLISM OF DIGOXIN IN NORMAL SUBJECTS | Q76970214 | ||
| The biotransformation of drugs in renal failure | Q67561630 | ||
| High-pressure liquid chromatographic analysis of drugs in biological fluids. V. Analysis of acebutolol and its major metabolite | Q67656332 | ||
| Pharmacokinetics of diflunisal elimination in patients with renal insufficiency [proceedings] | Q67691173 | ||
| Correction of protein binding defect in uremic sera by charcoal treatment | Q67783841 | ||
| Quantitation in plasma and urine of acebutolol and a major metabolite with preliminary observations on their disposition kinetics in man | Q67820043 | ||
| Comparison of the acetylation of procainamide and sulfadimidine in man | Q67826140 | ||
| Diflunisal: a review of its pharmacological properties and therapeutic use in pain and musculoskeletal strains and sprains and pain in osteoarthritis | Q28276373 | ||
| Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions | Q28293466 | ||
| Clinical consequences of polymorphic acetylation of basic drugs | Q28316730 | ||
| Clofibrate-induced muscle damage in patients with chronic renal failure | Q28317849 | ||
| Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure | Q28329448 | ||
| Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer | Q28331832 | ||
| Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function | Q28331990 | ||
| Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis | Q30449443 | ||
| Prediction of drug dosage in patients with renal failure using data derived from normal subjects | Q30658142 | ||
| Drug therapy. Sodium nitroprusside | Q33966356 | ||
| Cardio-Respiratory Toxicity of Propoxyphene and Norpropoxyphene in Conscious Rabbits* | Q34239932 | ||
| Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient | Q34285715 | ||
| Kinetics of salicylate elimination by anephric patients | Q34469570 | ||
| Plasma half-life of clofibric acid in renal failure | Q34517514 | ||
| Renal Failure, Drug Pharmacokinetics and Drug Action | Q35372914 | ||
| Beta-adrenoceptor blocking properties and cardioselectivity of M & B 17,803A | Q35600312 | ||
| Diseases and Drug Protein Binding | Q38243179 | ||
| Physiological disposition and metabolism of 5-(2',4'-difluorophenyl)salicyclic acid, a new salicylate | Q39067592 | ||
| N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis | Q39572187 | ||
| Disease and Acetylation Polymorphism | Q39636025 | ||
| Drug Prescribing in Renal Failure | Q39799026 | ||
| Polymorphic acetylation of procainamide in man | Q40325311 | ||
| Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease | Q40347145 | ||
| The pharmacokinetic profile of oxazepam | Q40574574 | ||
| The binding of drugs to plasma proteins from patients with poor renal function | Q40640466 | ||
| Drug dosage in renal disease | Q40640491 | ||
| Drug interactions and clinical pharmacokinetics | Q40640589 | ||
| Pharmacokinetics of oxazepam in healthy volunteers | Q40644403 | ||
| Oxazepam disposition in uremic patients | Q40644408 | ||
| Long-term antiarrhythmic therapy withN-acetylprocainamide | Q40700562 | ||
| The influence of polar and non-polar digoxin and digitoxin metabolites on the 86Rb-uptake of human erythrocytes and the contractility of guinea pig papillary muscles | Q41035776 | ||
| Electrophysiologic properties of propoxyphene and norpropoxyphene in canine cardiac conducting tissues in vitro and in vivo | Q41468732 | ||
| Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency | Q41481555 | ||
| Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation | Q41493977 | ||
| Acebutolol metabolite plasma concentration during chronic oral therapy | Q41509561 | ||
| Clofibrate disposition in renal failure and acute and chronic liver disease | Q41680184 | ||
| Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype | Q41690934 | ||
| Plasma levels and renal excretion of phenytoin and its metabolites in patients with renal failure | Q41731325 | ||
| Biotransformation and excretion of lorazepam in patients with chronic renal failure | Q41787246 | ||
| Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens | Q41844281 | ||
| Digoxin pharmacokinetics: multicompartmental analysis and its clinical implications | Q41913740 | ||
| Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype | Q42117649 | ||
| The polymorphic acetylation of sulphapyridine in man | Q42124596 | ||
| Decreased clearance of diflunisal in renal insufficiency--an alternative explanation | Q43118897 | ||
| Determination of acetylator status in uraemia | Q43241895 | ||
| Propranolol disposition in renal failure | Q43241986 | ||
| Decreased body clearance of diflunisal in renal insufficiency-an alternative explanation [letter] | Q43245169 | ||
| Active drug metabolites and renal failure | Q43522257 | ||
| Diphenylhydantoin Metabolism in Uremia | Q43563484 | ||
| Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man. | Q43712645 | ||
| Commentary: a physiological approach to hepatic drug clearance | Q43996648 | ||
| Kinetics of procainamide and N-acetylprocainamide in renal failure | Q44016141 | ||
| Adverse drug effects in relation to renal function | Q44340895 | ||
| Pharmacokinetics of acetaminophen elimination by anephric patients | Q44476272 | ||
| Pharmacokinetics in renal disease | Q44734595 | ||
| The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function | Q44979880 | ||
| Plasma propranolol levels in adults With observations in four children | Q45077479 | ||
| Polymorphic acetylation of sulphadimidine in normal and uraemic man | Q45163902 | ||
| Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors | Q45286897 | ||
| Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol | Q46122194 | ||
| Kinetic discrimination of three sulfamethazine acetylation phenotypes | Q46238473 | ||
| Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. | Q52939660 | ||
| The metabolism of antipyrine in patients with chronic renal failure | Q54368276 | ||
| Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: Comparison with procainamide | Q56474600 | ||
| Relation between serum quinidine levels and renal function. Studies in normal subjects and patients with congestive failure and renal insufficiency | Q57226563 | ||
| Diflunisal | Q57424497 | ||
| Renal clearance of oxipurinol, the chief metabolite of allopurinol | Q57480150 | ||
| Saliva and plasma levels and plasma protein binding of clofibrinic acid in uremic patients | Q58817395 | ||
| Elimination of procainamide in end stage renal failure | Q66916433 | ||
| Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods | Q66927591 | ||
| Polymorphic acetylation of procaine amide in healthy subjects | Q66939714 | ||
| Screening methods using sulfamethazine for determining acetylator phenotype | Q66958399 | ||
| Polymorphic Acetylation of the Antibacterials, Sulfamethazine and Dapsone, in South Indian Subjects * | Q66964667 | ||
| Clofibrate treatment of hyperlipidemia in chronic renal failure | Q67052110 | ||
| Determination of procainamide acetylator status | Q67242599 | ||
| Dose-dependent changes in sulfamethazine kinetics in rapid and slow isoniazid acetylators | Q67249995 | ||
| Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses | Q67251864 | ||
| Altered protein binding of diphenylhydamtoin in uremic plasma | Q67265856 | ||
| Is phenytoin metabolism dose-dependent by enzyme saturation or by feedback inhibition? | Q67340381 | ||
| Evidence for a trimodal pattern of acetylation of isoniazid in uremic subjects | Q67343212 | ||
| Inhibition of Drug Metabolism by Hydroxylated Metabolites: Cross‐Inhibition and Specificity | Q67356886 | ||
| Plasma concentration of ?-methyldopa and sulphate conjugate after oral administration of methyldopa and intravenous administration of methyldopa and methyldopa hydrochloride ethyl ester | Q67396568 | ||
| The predictable relationship between plasma levels and dose during chronic propranolol therapy | Q67403369 | ||
| N‐acetylprocainamide levels in patients with end‐stage renal failure | Q67443836 | ||
| Mechanisms of nonlinear disposition kinetics of sulfamethazine | Q67464116 | ||
| Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions | Q67483653 | ||
| Control of clofibrate toxicity in uremic hypertriglyceridemia | Q67548908 | ||
| Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases | Q67559812 | ||
| Spontaneous systemic lupus erythematosus and acelylator phenotype | Q67559814 | ||
| Drug distribution in renal failure | Q67561628 | ||
| P433 | issue | 5 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 329-345 | |
| P577 | publication date | 1981-09-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Drug metabolites in renal failure: pharmacokinetic and clinical implications | |
| P478 | volume | 6 |
| Q37895002 | A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. |
| Q43949330 | Antipyrine metabolite formation and excretion in patients with chronic renal failure |
| Q40157661 | Clinical Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs |
| Q39463386 | Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update |
| Q35825944 | Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. |
| Q51749898 | Disposition of alfentanil in patients receiving a renal transplant. |
| Q34708717 | Drug Prescribing in Renal Failure: Dosing Guidelines for Adults |
| Q28367622 | Drug dosage in patients with renal failure optimized by immediate concurrent feedback |
| Q37559261 | Drug dosing in patients with impaired renal function |
| Q42532053 | Drug metabolite concentration-time profiles: influence of route of drug administration |
| Q35637852 | Effects of renal diseases on the regulation and expression of renal and hepatic drug-metabolizing enzymes: a review. |
| Q37474175 | Effects of renal impairment on the pharmacokinetics of orally administered deferiprone |
| Q43780047 | Elimination of desacetyl cefotaxime in geriatric patients with multiple diseases |
| Q37972280 | Geriatric pharmacokinetics and the kidney |
| Q43241288 | Impaired elimination of lorazepam following subchronic administration in two patients with renal failure [letter] |
| Q39834679 | Interpretation of drug levels in acute and chronic disease states |
| Q49322022 | Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function |
| Q31147512 | Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion |
| Q46778997 | Medication dosing errors for patients with renal insufficiency in ambulatory care |
| Q71352655 | Metabolism of amitriptyline in patients with chronic renal failure |
| Q56832900 | Nonlinear kinetics of propafenone metabolites in healthy man |
| Q45048427 | Paracetamol disposition and metabolite kinetics in patients with chronic renal failure |
| Q40758038 | Pharmacokinetic optimisation of the treatment of osteoarthritis |
| Q36536031 | Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions. |
| Q37526589 | Pharmacokinetics and dosage adjustment in patients with renal dysfunction. |
| Q71256039 | Pharmacokinetics of quinine in patients with chronic renal failure |
| Q36313287 | Principles of pharmacotherapy: I. Pharmacodynamics |
| Q51686915 | Stereoselective interactions of ketoprofen glucuronides with human plasma protein and serum albumin |
| Q41830551 | Stereoselective pharmacokinetics of tocainide in human uraemic patients and in healthy subjects |
| Q72564519 | The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis |
| Q44035677 | The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure |
Search more.